Road to a Cure - ADC & SARM
Novel Treatments, Medical Community, Challenges and Barriers, Health Disparities, Diagnosis and Treatment, Entities of Cancer, MBC Imaging and Profiling, Immunotherapy, Difficult to Treat, Clinical Research, Long Term Adverse Effects Our MBClife Novel Treatments, Medical Community, Challenges and Barriers, Health Disparities, Diagnosis and Treatment, Entities of Cancer, MBC Imaging and Profiling, Immunotherapy, Difficult to Treat, Clinical Research, Long Term Adverse Effects Our MBClife

Road to a Cure - ADC & SARM

How famous is Dr Hope Rugo? She belongs to a tiny elite group of oncologists who have their own Wikipedia page. Dr. Dennis Slamon is quite possibly the only other member. Enough said. No surprise that we can’t wait to hear what she has to say about a new class of drugs, known as ADCs and specifically, the first ADC for mTNBC that already has a nickname – Sassy (sacituzumab govitecan). Do you know what a SARM is? It is a special class of drugs for those who are Androgen Receptor (AR) positive. Listen and find out.

Read More
Report Back from ASCO: What’s the Latest in Metastatic Breast Cancer
Novel Treatments, Medical Community, Clinical Research, Entities of Cancer, Updates from Conferences, Difficult to Treat, Obstacles to Better Outcomes Our MBClife Novel Treatments, Medical Community, Clinical Research, Entities of Cancer, Updates from Conferences, Difficult to Treat, Obstacles to Better Outcomes Our MBClife

Report Back from ASCO: What’s the Latest in Metastatic Breast Cancer

Are you living with ER+/HER2- or TNBC MBC and tired of hearing about new HER2 therapies and wondering when it will be your turn? Just after the meeting SHARE welcomed Dr. Timothy Pluard from University of Missouri-KC School of Medicine to a webinar highlighting promising data from trials and labs across the globe presented at the this year’s meeting,

Read More